Trilliant Health’s Post

A recent WHO study predicts over 35 million new diagnosed cases of cancer by 2050. There is a major need to optimize cancer care to improve outcomes and quality of life. By providing more in-depth information on cancer than ever before, advanced diagnostics could play a critical role in improving outcomes. They can, for example, be used to support earlier and more accurate diagnosis and the selection of highly tailored treatments that are more likely to be effective. We are thrilled to collaborate with industry leaders, alongside The Health Policy Partnership (#HPP), to develop a new report that outlines the policy actions needed to prepare health systems for the future of cancer diagnosis. The report, ‘Powering the future of cancer care with advanced diagnostics’, details the potential for these innovative techniques to transform outcomes for people with cancer, and outlines five priority areas where policymakers can support the widespread adoption of advanced diagnostics. 🔎 Read the report and find out more: https://lnkd.in/dm4RV-GR AstraZeneca | GE HealthCare | Ibex Medical Analytics | The Health Policy Partnership | Thomas Di Maio | Vijay Andani #HealthEquity #DataDrivenMedicine #PrecisionMedicine #AdvancedDiagnostics

𝗛𝗼𝘄 𝗙𝘂𝗻𝗱𝗶𝗻𝗴 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗦𝗮𝘃𝗲𝘀 𝗟𝗶𝘃𝗲𝘀 Every day, countless lives are impacted by breast cancer. Yet, amidst the challenges, there's hope – and that hope lies in funding breast cancer research. 💪🔬 𝗪𝗵𝘆 𝗶𝘀 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝗯𝗿𝗲𝗮𝘀𝘁 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘀𝗼 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹? 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 & 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆: Funding drives innovation, leading to breakthroughs in detection, treatment, and prevention strategies. It empowers researchers to explore new avenues, ultimately saving lives. 𝗘𝗮𝗿𝗹𝘆 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻: With sufficient funding, researchers can delve deeper into understanding breast cancer's complexities, allowing for earlier detection methods and personalized treatment plans tailored to each patient. 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗖𝗮𝗿𝗲: Research funding supports clinical trials, providing patients with access to cutting-edge therapies and ensuring advancements reach those who need them most, thereby improving survival rates and quality of life. 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝗘𝗳𝗳𝗲𝗰𝘁: Beyond medical breakthroughs, funding breast cancer research fosters community support, education, and advocacy efforts, empowering individuals to take control of their health and spread awareness. Together, through our support and collaboration, we can drive meaningful change and bring us closer to a future free from this disease. 💗#BreastCancerResearch #BeTheEnd #TakeTheChallenge

Cancer care is expensive, and mistreating patients adds to that expense, particularly in human costs. When patients with rare or complex cancers have access to care at a comprehensive cancer center, they often experience better outcomes at lower costs. Data show significant differences in outcomes, including survival, when a patient is seen in an NCI-designated comprehensive cancer center versus non-academic settings. In the last 10 years, the field of oncology has undergone transformational change. Advances in our understanding of genomics have spearheaded an overhaul in our approach to cancer diagnosis, treatment and monitoring. Today, our managed care programs often create barriers to such access, and this can lead to misdiagnoses and mistreatment that can often mean unnecessary exposure to toxic chemotherapy, suffering or avoidable death. These outcomes can be avoided with effective policy. Read the blog by Harlan Levine, M.D., President, Health Innovation and Policy, City of Hope 📖 https://ow.ly/SKFb50Qio6w #healthequity #healthcare #healthpolicy

🎗️ Exciting News in the Battle Against Cancer 🌍   We are thrilled to announce that Further Group has entered into a transformative partnership with Massive Bio, combining our strengths to revolutionize global access to cancer clinical trials.    Further Group, known for our comprehensive serious illness solutions within the insurance sector, is taking a giant leap forward. Our mission to dismantle barriers to advanced medical treatments has found a powerful ally in Massive Bio’s innovative artificial intelligence technology.   Together, we're paving a new way for cancer care, focusing on personalized treatment through enhanced clinical trial matching - ensuring patients worldwide can benefit from the latest advancements in oncology.    🗣️ Hear it from our leaders: Toygun Onaran, CFO at Massive Bio, adds, "It's a significant milestone in our mission to democratize cancer care, ensuring personalized, innovative treatments reach every corner of the globe." Ana Antunes, Head of Global Operations at Further Group, states, "This partnership with Massive Bio marks a revolution in cancer care, expanding horizons for patients and their loved ones."   Let's join hands in celebrating this milestone and spreading the word. Every shared step is a step closer to a world where no distance, no matter how great, can keep the hope of cutting-edge treatment away from cancer patients.    Learn more:  https://lnkd.in/df4Yn2cJ   Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu, Toygun Onaran #FurtherGroup #MassiveBio #CancerCare #ClinicalTrials #Innovation #HealthTech #Partnership #GlobalHealth #ArtificialIntelligence #Oncology #Hope

The transformative role of digital health innovations in cancer care is a hot topic at #ASCO24 in Chicago, one of the most significant gatherings of oncologists worldwide. Even as 5-year cancer survival rates have increased, the rates of more than a dozen cancers are rapidly rising around the world among adults under age 50. Models based on global data predict the number of early-onset cancer cases will increase by 30% by 2030. In the U.S., colorectal cancer has become the leading cause of cancer death among men under 50. It’s the second leading cause of cancer death in young women. #Digitalhealth solutions can play a significant role in cancer care, earlier detection, and more effective prevention. 🧬 #AI-driven diagnostics can facilitate earlier and more accurate detection 🧬 #Telemedicine platforms can bridge distance gaps to secure more timely consultations 🧬 #Quantum technologies can accelerate drug discovery and the development of personalized drug treatment plans 🧬 #Bigdata analytics can shape and sharpen treatment plans (a big discussion point at ASCO), supported by a steady flow of data from wearables and remote patient monitoring technologies 🧬 #Mobileapps for mental health support can be tailored to support cancer patients (a lot of energy around this as an under-discussed and under-served component of cancer care) As our Ascent Strategy Group team makes the rounds, presents our new tools, and establishes new collaborations, we’ve been lifted by the passion among attendees to serve patients. That passion is palpable, powerful and inspirational. #oncology #oncologists #cancercare

On the heels of the recent report “Getting Better, Faster: The Case for Optimizing Access to Precision Medicines in the Wake of the Revolution in Cancer Care” from the team at CONECTed, this article by Louise Binder Martine Elias gets to the point: “It's time that our governments addressed the fragmented health-care systems and complex regulatory and pricing models that are blocking #access to the #innovative #therapies people living with cancer need to survive.” https://lnkd.in/e3huy24c CC: Healthing Lisa Machado  #specialtypharmaceuticals #Canada #healthequity #patientequity #equity #equality #realworlddata #realworldevidence #healthoutcomes #data #patientsfirst #access #drugaccess #precisionmedicine #cancer

Tumor markers are invaluable tools in the fight against cancer. They offer insights into disease progression, treatment efficacy, and patient outcomes. 💪 #TumorMarkers #CancerResearch #MedicalAdvancements 🔍 Recent breakthroughs have led to more precise and personalized approaches to cancer care, giving hope to patients and their families. 🌟 Here are some key takeaways: 1. Early Detection: Tumor markers play a crucial role in early cancer detection, enabling timely intervention when it matters most. #EarlyDetection #CancerAwareness 2. Treatment Tailoring: With advancements in tumor marker research, treatment plans can be customized to target specific cancer types, optimizing therapeutic outcomes. #PrecisionMedicine #PersonalizedTreatment 3. Monitoring Progress: Tumor markers provide real-time data on treatment response, allowing healthcare providers to make informed decisions and adjust therapies as needed. #TreatmentMonitoring #PatientCare 4. Research Collaboration: The collaboration between researchers, clinicians, and healthcare institutions is vital in advancing our understanding of tumor markers and their clinical applications. #Collaboration #MedicalInnovation Together, we can make a difference in the fight against cancer! 🤝💕 #TumorMarkers #CancerResearch #MedicalAdvancements #CancerAwareness #PrecisionMedicine #TreatmentMonitoring #Collaboration #ScientificAdvancements

New Cancer Diagnosis Hitting Record Highs, Driven by Disturbing Increase Among Young People Cancer is on the rise in the U.S., most notably among people under 50 years old, according to a new study. The American Cancer Society on Wednesday published the results of a survey of data, concluding that the country should expect to see more than 2 million new diagnosis of cancer in 2024. The study also estimated that roughly 612,000 people will die of cancer in 2024, a small increase from last year. There was some good news in the study: cancer rate dropped slightly among those 65 and older, and Americans in the 50-64 age group saw their rates of the disease "largely stable" over the last three decades. Notably, people aged younger than 50 years were the only one of these three age groups to experience an increase in overall cancer incidence during this time period, the survey said. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

Increasingly, cancer is becoming a chronic disease among working Canadians. In fact, two out of five Canadians are expected to develop cancer in their lifetime, and many of those diagnoses will occur in working Canadians between the ages of 20 - 65. At Pfizer, we continue to take bold new approaches to translate scientific research into new medicines for people living with cancer. We also firmly believe appropriate cancer care can significantly impact the lives of patients. This is why we are committed to ensuring our colleagues are well supported should they experience a cancer diagnosis and have broad access to novel treatments if they need them. To learn more about how employers can best support their employees living with cancer, visit www.cancerandwork.ca. #EmployeeHealth #CancerJourney #WorkplaceWellbeing

Say what you want about funding issues, fuzzy politics and burnout, but it all doesn't matter much when people are dying while waiting for someone to figure things out. #whywait #patientvoices #access #healthing #innovativetherapies #precisionmedicine #enoughisenough #dontwantowait